Waters Corporation: Launching A Bioseparations Power Surge With Breakthrough Large-Molecule Innovations!

Waters Corporation’s third-quarter results for 2025 demonstrated significant momentum, reflecting strong execution and strategic positioning. The company reported an 8% increase in sales on both a reported and constant currency basis, with notable growth in both instruments and recurring revenue streams. Instrument sales were bolstered by high single-digit growth in the LC-MS portfolio, while recurring revenue saw a 9% increase, driven by robust performances in service and chemistry, particularly in the bioseparations segment. The quarterly results exceeded expectations, underscoring the company’s successful innovation and market expansion efforts. Earnings per share on a non-GAAP basis grew by 16% to $3.40, further illustrating Waters’ capacity to leverage its operational strengths and market opportunities. Notably, the company’s performance was driven by several factors, including a new instrument replacement cycle that began last year, which continues to spur sales activity and generate a strong pipeline.